Synthesis and antibacterial activity of 7-(1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-7-yl) quinolones

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 17, 2009, Pages 4933-4936

  Zhu, Bin ^a   Marinelli, Brett A ^a   Goldschmidt, Raul ^a   Foleno, Barbara D ^a   Hilliard, Jamese J ^a   Bush, Karen ^a   Macielag, Mark J ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antibacterial agent; Quinolone

Indexed keywords

7 (1,2,3,4 TETRAHYDROPYRROLO[1,2 A]PYRAZIN 7 YL)QUINOLONE DERIVATIVE; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ESCHERICHIA COLI; MOUSE; NONHUMAN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; MICE; MICROBIAL SENSITIVITY TESTS; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP;

NEGIBACTERIA; POSIBACTERIA; STREPTOCOCCUS PNEUMONIAE;

EID: 68349155541     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.087     Document Type: Article

References (21)

1. Lesher G.Y., Froelich E.J., Gruett M.D., Bailey J.H., and Brundage R.P. J. Med. Chem. 5 (1962) 1063
2. For some recent reviews, see:. Ball P. J. Antimicrob. Chemother. 46 (2000) 17
3. Appelbaum P.C., and Hunter P.A. Int. J. Antimicrob. Agents 16 (2000) 5
4. Andriole V.T. Clin. Infect. Dis. 41 (2005) S113
5. Bambeke F.V., Michot J.M., Eldere J.V., and Tulkens P.M. Clin. Microbiol. Infect. 11 (2005) 256
6. Mitscher L.A. Chem. Rev. 105 (2005) 559
7. Wise R., Andrews J.M., and Edwards L.J. Antimicrob. Agents Chemother. 23 (1983) 559
8. Grobe K., and Heitzer H. Liebigs Ann. Chem. (1987) 29
9. Atarashi S., Yokohama S., Yamamzaki K., Sakano K., Imamura M., and Hayakawa I. Chem. Pharm. Bull. 35 (1987) 1896
10. Une T., Fujimoto T., Sato K., and Osada Y. Antimicrob. Agents Chemother. 32 (1988) 559
11. For selected examples, see:. Carabateas P.M., Brundage R.P., Gelotte K.O., Gruett M.D., Lorenz R.R., Opalka C.J., Singh B., Thielking W.H., Williams G.L., and Lesher G.Y. J. Heterocycl. Chem. 21 (1984) 1857
12. Reuman M., Daum S.J., Singh B., Wentland M.P., Perni R.B., Pennock P., Carabateas P.M., Gruett M.D., Saindane M.T., Dorff P.H., Coughlin S.A., Sedlock D.M., Rake J.B., and Lesher G.Y. J. Med. Chem. 38 (1995) 2531
13. Todo Y., Takagi H., Iino F., Fukuoka Y., Takahata M., Okamoto S., Saikawa I., and Narita H. Chem. Pharm. Bull. 42 (1994) 2569
14. Laborde E., Kiely J.S., Culberton T.P., and Lesheski L.E. J. Med. Chem. 36 (1993) 1964
15. Takahata M., Mitsuyama J., Yamashiro Y., Yonezawa M., Araki H., Todo Y., Minami S., Watanabe Y., and Narita H. Antimicrob. Agents Chemother. 43 (1999) 1077
16. Hayashi K., Takahata M., Kawamura Y., and Todo Y. Arzneimittel-Forschung 52 (2002) 903
17. Pfitzner K.E., and Moffatt J.G. J. Am. Chem. Soc. 87 (1965) 5661
18. Takagi J., Takahashi K., Ishiyama T., and Miyaura N. J. Am. Chem. Soc. 124 (2002) 8001
19. For preparation of 7-OTf intermediate, see:. Kiely J.S., Laborde E., Lesheski L.E., and Bucsh R.A. J. Heterocycl. Chem. 28 (1991) 1581
20. The minimum inhibitory concentrations (MICs) were determined by the broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) guidelines. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 5th ed.; Approved standard: NCCLS Document M7-A5, 2000.
21. The in vivo efficacies of compound 1e and ciprofloxacin were tested in female Swiss-Webster mice infected ip with Staphylococcus aureus subsp. aureus ATCC13709. Mice were dosed subcutaneously and orally with test compound at 1 h following infection. Mortality was observed over a period of three days. A group of infected mice not treated with drug served as controls.